Display options
Cite
Imyanitov EN, Iyevleva AG. Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. Cancer Lett. 2021;526:41-52doi: 10.1016/j.canlet.2021.11.021.
Imyanitov, E. N., & Iyevleva, A. G. (2022). Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. Cancer letters, 52641-52. https://doi.org/10.1016/j.canlet.2021.11.021
Imyanitov, Evgeny N, and Iyevleva, Aglaya G. "Molecular tests for prediction of tumor sensitivity to cytotoxic drugs." Cancer letters vol. 526 (2022): 41-52. doi: https://doi.org/10.1016/j.canlet.2021.11.021
Imyanitov EN, Iyevleva AG. Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. Cancer Lett. 2022 Feb 01;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20. PMID: 34808283.
Copy Download .nbib Format: NLM
Share it on

Cancer Lett. 2022 Feb 01;526:41-52. doi: 10.1016/j.canlet.2021.11.021. Epub 2021 Nov 20.

Molecular tests for prediction of tumor sensitivity to cytotoxic drugs.

Cancer letters

Evgeny N Imyanitov, Aglaya G Iyevleva

Affiliations

  1. Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, St.-Petersburg, 197758, Russia; Department of Medical Genetics, St.-Petersburg Pediatric Medical University, St.-Petersburg, 194100, Russia; Department of Oncology, I.I. Mechnikov North-Western Medical University, St.-Petersburg, 191015, Russia. Electronic address: [email protected].
  2. Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, St.-Petersburg, 197758, Russia; Department of Medical Genetics, St.-Petersburg Pediatric Medical University, St.-Petersburg, 194100, Russia.

PMID: 34808283 DOI: 10.1016/j.canlet.2021.11.021

Abstract

Chemotherapy constitutes the backbone of cancer treatment. Several predictive assays assist personalized administration of cytotoxic drugs and are recommended for use in a clinical setting. The deficiency of DNA repair by homologous recombination (HRD), which is caused by inactivation of BRCA1/2 genes or other genetic events, is associated with high tumor responsiveness to platinum compounds, bifunctional alkylating agents and topoisomerase II poisons. Low activity of MGMT predicts the efficacy of nitrosoureas and tetrazines. Some clinically established pharmacogenetic tests allow for the adjustment of drug dosage, for example, the analysis of DPYD allelic variants for administration of fluoropyrimidines and UGT1A1 genotyping for the use of irinotecan. While there are promising molecular predictors of tumor sensitivity to pemetrexed, gemcitabine and taxanes, they remain in the investigational stage and require additional validation. Comprehensive molecular analysis of tumors obtained from drug responders and non-responders is likely to reveal new clinically useful predictive markers for cytotoxic therapy.

Copyright © 2021 Elsevier B.V. All rights reserved.

Keywords: Chemotherapy; Cytotoxic drugs; Expression; Gene; Mutation; Polymorphisms; Predictive markers

Publication Types